Literature DB >> 6826488

Anti-influenza A activity of combinations of amantadine and ribavirin in ferret tracheal ciliated epithelium.

D B Burlington, G Meiklejohn, S R Mostow.   

Abstract

The anti-influenza A activities of amantadine and ribavirin were investigated separately and in combination. Ferret tracheal ciliated epithelium was continuously exposed to the drugs at concentrations (0.25, 0.5, and 1 mg/l) comparable to those found in human serum after oral administration. Each drug alone produced a modest delay in A/Alaska/6/77 (H3N2) induced cytopathic effect. The combination of drugs synergistically delayed cytopathic effect. At 1 mg/l of each, cytopathic effect was prevented in 75% of rings for the 28-day duration of the experiment. This effect was greater than that of 32 mg/l of amantadine or 64 mg/l of ribavirin as single antiviral drugs. Peak virus production was suppressed 4.4 log-fold by the combination of 1 mg/l of each drug. This is in contrast to amantadine alone which suppressed peak virus production by 1 log-fold and ribavirin along which at 1 mg/l suppressed peak virus production by 1.9 log-fold. At lower concentrations, the drugs were at least additive in suppression of virus production.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826488     DOI: 10.1093/jac/11.1.7

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.

Authors:  J J Kirsi; P A McKernan; N J Burns; J A North; B K Murray; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 3.  Antiviral combinations for severe influenza.

Authors:  Jake Dunning; J Kenneth Baillie; Bin Cao; Frederick G Hayden
Journal:  Lancet Infect Dis       Date:  2014-09-08       Impact factor: 25.071

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.